- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04239326
Clinical Evaluation of tNGS for Diagnosis of DR-TB (Seq&Treat)
Multicentre Clinical Trial to Assess the Performance of Culture-free, End-to-end Targeted NGS (tNGS) Solutions for Diagnosis of Drug Resistant TB (DR-TB)
Current rapid molecular assays for detection of drug-resistant TB from direct clinical samples have important limitations. They are not suited for high-throughput settings; can only be used to detect a limited number of target gene regions and are not ideal for detection of phenotypic resistance conferred by mutations across large gene regions (e.g. pyrazinamide).
Culture-free, end-to-end targeted NGS (tNGS) Solutions for Diagnosis of Drug Resistant TB can offer higher throughput and greater accuracy across more TB drugs than current WHO endorsed molecular assays, and a significantly faster time to result than phenotypic drug susceptibility testing (DST).
Evidence regarding the clinical diagnostic accuracy and operational characteristics of tNGS solutions is needed to comprehensively evaluate tNGS for diagnosis of drug-resistant TB among patients who have been diagnosed with TB, and will be critical to inform global and national policy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In recent years, tuberculosis (TB) control efforts have been complicated by the rise and spread of MDR-TB, or TB that is resistant to the first-line drugs isoniazid (INH) and rifampicin (RIF), and XDR-TB, or MDR-TB that has developed additional resistance to a fluoroquinolone (FQ) and any of the second-line injectable compounds (SLI) [amikacin (AMK), kanamycin (KAN) and/or capreomycin (CAP)] The rapid diagnosis and appropriate treatment of M/XDR-TB is essential to prevent significant morbidity, mortality and further transmission of disease. For treatment of uncomplicated MDR-TB, the World Health Organization (WHO) recently endorsed a 6-9 month treatment regimen, replacing conventional 18-24 month regimens. The FQs and SLIs are key components of the 6-9 month regimen, and so it is necessary to rule-out resistance to these compounds prior to treating patients with the shorter regimen. For longer MDR-TB treatment regimens, WHO no longer endorses the use of CAP or KAN, but the regimens still rely heavily on FQs, with AMK and PZA listed as recommended Group C drugs, thus ensuring that the rapid diagnosis of all of these drugs is still relevant and critical to the timely treatment of DR-TB4.
The current standard for comprehensive DR-TB diagnosis is culture-based DST (liquid culture, e.g. MGIT or solid culture, e.g. LJ), which can only be implemented in custom-built Biosafety Level 3 (BSL3) laboratories. The global response to the need for comprehensive DST in the last two decades has therefore been focused on the scale-up of BSL3 facilities and MGIT liquid culture systems to expand global capacity. While this enabled some standardization of DST workflows and resulted in a foundation for a global network of reference TB laboratories, it has come at considerable cost and effort in terms of infrastructure needs, significant hands-on time and expertise for routine use. Moreover, the slow growth of Mycobacterium tuberculosis (Mtb) in culture means it takes 6-8 weeks to get results from conventional culture-based DST and data has shown that often culture comes too late to have an impact on the patient outcomes. More recently, the global response to the public health need for universal DST has been a wide rollout and broad adoption of rapid molecular TB tests with limited DST capabilities to support early treatment decisions and complement traditional phenotypic DST, e.g. (Cepheid Xpert MTB/RIF or Ultra, Hain GenoType MTBDRplus). However, the inherent design of probe- or array-based molecular diagnostics limits their coverage to a limited number of specific mutations included in the initial design-locked assay, and prevents them from integrating new mutations and new drug resistance prediction without going back to complete product development and validation. Next generation sequencing (NGS) technology has the potential to revolutionize global comprehensive DST. Targeted NGS (tNGS) can be used to interrogate more than numerous genome-wide targets in the Mycobacterium tuberculosis (MTB) that contain mutations associated with resistance, and differentiate them from mutations that do not confer resistance, providing better performance than probe or array-based molecular diagnostics.
For DR-TB diagnosis, tNGS offers huge potential gains over culture-based methods and other molecular diagnostics in terms of speed, ease of use and comprehensive coverage. However, the uptake of sequencing for DR-TB patient care in LMICs has been limited due to (i) the absence of a standardized and complete solution directly from clinical samples to data analysis and interpretation (i.e. an end-to-end solution); (ii) lack of verification and validation of such commercial end-to-end sequencing solutions to drive policy and guidelines for use of sequencing as an in vitro diagnostic; and (iii) perceived technical and cost barriers. The WHO and FIND developed a technical guide on requirements and utilization of sequencing for clinical diagnosis of DR-TB and a consensus-based Target Product Profile (TPP) for sequencing. The standard components of an End-to-end solution include: DNA extraction from sputum sample, library preparation, sequencing and data analysis/interpretation for clinical result reporting. Based on the published TPP guidelines, a number of manufacturers have developed end-to-end solutions for DR-TB diagnosis. These sequencing solutions require rigorous analytical testing, laboratory validation, and clinical evaluation in order to ensure that they meet technical as well as operational target product profile criteria.
The current study is part of a two-phase project to assess performance of culture-free, tNGS end-to-end solutions for drug resistant TB diagnosis, and to recommend their use in diverse clinical settings.
- Phase 1 is an analytical study performed at the manufacturer site. It is a blinded laboratory analytical validation of tNGS end-to-end solutions using a well-characterized panel of MTB strains.
- Phase 2 (the current study) is a multi-centre, clinical trial to evaluate the diagnostic accuracy and performance of up to 3 tNGS end-to-end sequencing solutions in settings of intended use.
The two study phases will provide complementary bodies of evidence to address the study objectives and determine whether tNGS solutions meet the diagnostic performance criteria outlined in the NGS Target Product Profile (TPP) for clinical diagnosis of drug resistant TB. The purpose of this clinical trial is to confirm accuracy estimates observed in the laboratory validation study and ensure that tNGS diagnostic performance characteristics are consistent at sites of intended use.
The focus of this protocol is the multi-centre clinical evaluation of the diagnostic accuracy and technical performance of End-to-end tNGS solutions for DR-TB diagnosis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Pamela Nabeta, MD
- Phone Number: +41 22 710 27 87
- Email: Pamela.Nabeta@finddx.org
Study Contact Backup
- Name: Andres De la Rossa, PhD
- Phone Number: +41 79 881 47 05
- Email: Andres.DelaRossa@finddx.org
Study Locations
-
-
-
Tbilisi, Georgia, 380060
- National Center for Tuberculosis and Lung Diseases
-
-
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 40016
- Hinduja Hospital and Medical Research Centre
-
-
-
-
Sandringham
-
Johannesburg, Sandringham, South Africa, 2192
- National Institute for Communicable Diseases & Wits Health Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- A TB-positive result by Xpert MTB/RIF OR Xpert MTB/RIF Ultra (i.e. "MTB DETECTED") at or prior to enrollment, AND
At risk for drug resistant TB based on at least one of the following risk factors:
A. A positive RIF-resistance result by Xpert MTB/RIF OR Xpert MTB/RIF Ultra (i.e."RIF resistance DETECTED") OR B. Not responding TB treatment with positive sputum smear or culture after ≥ 3 months of standard TB treatment. OR C. Previously diagnosed with Rif-resistant/MDR-TB and failed TB treatment with positive sputum smear or culture after ≥ 3months of a standard MDR-TB regimen OR D. Previously received >1 month of treatment for a prior TB episode OR E. Close contact with a known drug-resistant TB case AND
- Willing to provide sputum AND
- 18 years of age and older (or legal adult age corresponding to the site) AND
- Provision of signed informed consent
Exclusion Criteria:
- Have started treatment for current TB episode more than 7 days prior to date of enrolment (i.e. must have been on treatment for less than 7 days for this TB treatment episode at enrolment) OR
- Institutionalized or imprisoned
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Point estimates, with 95% confidence intervals, of sensitivity and specificity for RIF resistance detection for each of up to 3 tNGS solutions
Time Frame: January 2021 - March 2021
|
Outcomes 1.1 to 1.5 will be evaluated on the PP population.
Point estimates (with 95% CI) of sensitivity and specificity will be derived based on pooled data for all sites.
In order to assess whether there is an association between the results and the clinical site from where the samples were collected, the estimates of sensitivity and specificity for each site will be compared with each other by use of a Pearson's chi-squared test, at a significance level of 5%, adjusted by Bonferroni correction for the total number of tests performed.
A random effect model will be used if it is believed that a high site-effect is present: this will be assessed by the evaluation of heterogeneity using Cochran's Q (with a significance level set at 0.1) and the I2 statistics (with a value >0.5).
|
January 2021 - March 2021
|
Point estimates, with 95% confidence intervals, of sensitivity and specificity for INH resistance detection for each of up to 3 tNGS solutions
Time Frame: January 2021 - March 2021
|
Outcomes 1.1 to 1.5 will be evaluated on the PP population.
Point estimates (with 95% CI) of sensitivity and specificity will be derived based on pooled data for all sites.
In order to assess whether there is an association between the results and the clinical site from where the samples were collected, the estimates of sensitivity and specificity for each site will be compared with each other by use of a Pearson's chi-squared test, at a significance level of 5%, adjusted by Bonferroni correction for the total number of tests performed.
A random effect model will be used if it is believed that a high site-effect is present: this will be assessed by the evaluation of heterogeneity using Cochran's Q (with a significance level set at 0.1) and the I2 statistics (with a value >0.5).
|
January 2021 - March 2021
|
Point estimates, with 95% confidence intervals, of sensitivity and specificity for fluoroquinolone (moxifloxacin, levofloxacin) resistance detection for each of up to 3 tNGS solutions
Time Frame: January 2021 - March 2021
|
Outcomes 1.1 to 1.5 will be evaluated on the PP population.
Point estimates (with 95% CI) of sensitivity and specificity will be derived based on pooled data for all sites.
In order to assess whether there is an association between the results and the clinical site from where the samples were collected, the estimates of sensitivity and specificity for each site will be compared with each other by use of a Pearson's chi-squared test, at a significance level of 5%, adjusted by Bonferroni correction for the total number of tests performed.
A random effect model will be used if it is believed that a high site-effect is present: this will be assessed by the evaluation of heterogeneity using Cochran's Q (with a significance level set at 0.1) and the I2 statistics (with a value >0.5).
|
January 2021 - March 2021
|
Point estimates, with 95% confidence intervals, of sensitivity and specificity for second-line injectable (amikacin, capreomycin, kanamycin) resistance detection for each of up to 3 tNGS solutions
Time Frame: January 2021 - March 2021
|
Outcomes 1.1 to 1.5 will be evaluated on the PP population.
Point estimates (with 95% CI) of sensitivity and specificity will be derived based on pooled data for all sites.
In order to assess whether there is an association between the results and the clinical site from where the samples were collected, the estimates of sensitivity and specificity for each site will be compared with each other by use of a Pearson's chi-squared test, at a significance level of 5%, adjusted by Bonferroni correction for the total number of tests performed.
A random effect model will be used if it is believed that a high site-effect is present: this will be assessed by the evaluation of heterogeneity using Cochran's Q (with a significance level set at 0.1) and the I2 statistics (with a value >0.5).
|
January 2021 - March 2021
|
Point estimates, with 95% confidence intervals, of sensitivity and specificity for pyrazinamide (PZA) resistance detection for each of up to 3 tNGS solutions
Time Frame: January 2021 - March 2021
|
Outcomes 1.1 to 1.5 will be evaluated on the PP population.
Point estimates (with 95% CI) of sensitivity and specificity will be derived based on pooled data for all sites.
In order to assess whether there is an association between the results and the clinical site from where the samples were collected, the estimates of sensitivity and specificity for each site will be compared with each other by use of a Pearson's chi-squared test, at a significance level of 5%, adjusted by Bonferroni correction for the total number of tests performed.
A random effect model will be used if it is believed that a high site-effect is present: this will be assessed by the evaluation of heterogeneity using Cochran's Q (with a significance level set at 0.1) and the I2 statistics (with a value >0.5).
|
January 2021 - March 2021
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Point estimates, with 95% confidence intervals, of sensitivity and specificity for additional second-line resistance detection (bedaquiline, linezolid, clofazimine, streptomycin) for up to 3 tNGS solutions.
Time Frame: January 2021 - March 2021
|
January 2021 - March 2021
|
Comparison of drug-specific point estimates of sensitivity and specificity (with 95% confidence intervals) for up to 3 tNGS solutions against Hain MTBDRplus/sl drug-specific results.
Time Frame: January 2021 - March 2021
|
January 2021 - March 2021
|
Comparison of overall test success rate (defined as the total number of full profiles i.e. calls across all drug targets) in up to 3 tNGS solutions against success rate in Xpert MTB/RIF and Hain MTBDRplus/sl.
Time Frame: January 2021 - March 2021
|
January 2021 - March 2021
|
Summary of technical performance characteristics in up to 3 tNGS solutions including invalid and indeterminate rates, ease of use metrics, and other operational characteristics
Time Frame: January 2021 - March 2021
|
January 2021 - March 2021
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TB038
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis, Multidrug-Resistant
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug-resistant TuberculosisSouth Africa, Estonia, Philippines, Peru, Lithuania, Latvia, Moldova, Republic of
-
Janssen Research & Development, LLCRecruitingMultidrug-Resistant TuberculosisMozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
-
University of Cape TownBaylor Research InstituteCompletedMultidrug-resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingTuberculosis, MDRHaiti, Tanzania, Thailand, Botswana, Brazil, India, Kenya, Peru, Philippines, South Africa, Uganda, Zimbabwe, Vietnam
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedTuberculosisLatvia, Lithuania
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug Resistant TuberculosisPhilippines, South Africa
-
Huashan HospitalUnknownMultidrug Resistant TuberculosisChina
Clinical Trials on targeted Next Generation Sequencing (tNGS)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingInfections | Critical Illness | Diagnosis
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); University Hospital... and other collaboratorsNot yet recruitingDrug-resistant Tuberculosis | Cost-Benefit Analysis | HIV CoinfectionSouth Africa
-
Military University Hospital, PragueUnknown
-
Asan Medical CenterRecruitingPancreatic Cancer | Chemotherapy Effect | Genetic ChangeKorea, Republic of
-
Qingyuan ZhanNot yet recruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingBiliary Tract Cancer (BTC)Taiwan
-
Konkuk University Medical CenterFoundation Medicine; Roche DiagnosticsRecruitingAdenocarcinoma of Lung | EGFR Activating MutationKorea, Republic of
-
Xiangya Hospital of Central South UniversityHunan Cancer Hospital; The Third Xiangya Hospital of Central South University; Hunan Provincial People's Hospital and other collaboratorsCompletedBladder Cancer | Urine | Diagnosis | BiomarkerChina
-
University Hospital HeidelbergFraunhofer Institute for Interfacial Engineering and Biotechnology; Dietmar...CompletedSepsis | Septic ShockGermany
-
Rothman Institute OrthopaedicsEnrolling by invitation